UK: Life Sciences Issues In Corporate Transactions – Part 2

Last Updated: 17 June 2016
Article by Colin McCall

In the second part to 'Life Sciences issues in corporate transactions', published in the January edition of Synapse, Colin McCall discusses the development cycle and the patent cliff and other matters important to the life science sector, including biosimilars, orphan medicines, parallel imports and compulsory licences.


Intellectual property protection is vital to maximising the benefit of R&D in the life sciences. Technological improvements, especially when embodied in commercial products, tend to be fairly transparent and therefore available to potential competitors. Such competitors can therefore acquire knowledge about new medicinal products within a reasonably short period of time and with a relatively modest R&D effort of their own.

In order to understand the benefit of IP protection and the effect of the 'patent cliff', an understanding of the development cycle of a successful medicinal product is important. Early phases in the development cycle, such as discovery and preclinical and clinical phases are typically characterised by initially low but rapidly increasing improvements in the medicinal product (eg, preferred formulations, efficient manufacturing processes, new indications, dosing regimen, etc) as development issues are ironed out, but accompanied by negative total revenue given the huge costs associated with discovery and clinical development. During the intermediate phases of post-marketing approval and then peak sales improvements become increasingly hard to achieve but revenues rapidly increase. In the later stages of generic competition and commoditisation little or no performance improvements are possible and revenues in respect of the product diminish.

In Figures 1 and 2 the columns each represent a phase during the development cycle: A = research (ie, discovery); B = preclinical and clinical phase; C = post-marketing approval; D = peak sales; E = generic competition/product substitution; and F = fully commoditised/obsolescence.

The time at which competition occurs is known as the patent cliff and will depend entirely on the strength of the IP portfolio the initial developer has managed to acquire. When the patent cliff is reached, the revenues available to all market entrants in respect of the product rapidly collapse. But it is the patent holder that loses most. By way of example, the best-selling drug in history, Pfizer's Lipitor had peak sales of around $11 billion per annum in 2009 and 2010 before going off patent in 2011. Since then Pfizer's sales of Lipitor collapsed to $2 billion for 2013. Indeed, in the last five years according to an IMS report1 the patent cliff has caused losses in revenue to innovator pharmaceutical companies of $154 billion.

The costs/revenues shown in the development cycle curve in Figure 1 represent the costs/revenues spent or achieved by all market entrants in respect of a given medicinal product as a whole and not just the costs/revenue of the first life sciences company to develop the new medicinal product. It will be the first developer that incurs almost all of the cost and derives almost all of the revenue up until the patent cliff. Thereafter, the revenues are shared by all market entrants.

The longer a life sciences company can prevent competition and delay the patent cliff, the longer it can prevent price erosion and the greater the proportion of the available revenues from a particular product it can keep for itself. In order for life sciences companies to weather the storm of patent cliff faces they must continually bring new medicinal products to market through a development pipeline. Historically these pipelines have been derived through internal R&D efforts, but increasingly, larger life sciences companies are seeking to bolster their development pipeline with the acquisition of smaller-cap life sciences companies with late-stage development products through corporate transactions or through in-licensing deals. Accordingly, early-stage life sciences companies that have broad IP protection in respect of their core technologies are much more attractive investment propositions.



Improvements in technology and pressures to diversify business models away from small molecule drugs are just two of the factors that are focusing attention on biological medicinal products (ie, medicinal products that are made by a living organism, such as a bacterium or yeast and can consist of relatively small molecules such as human insulin or erythropoietin, or complex molecules such as monoclonal antibodies). This has led to a rise in biosimilars.

Biosimilars are biological medicinal products that are similar to another biological product that has already been authorised and that do not differ significantly from the original product in terms of quality, safety and efficacy. As such, biosimilars are copies of biological medicines that are already approved.

There is no formal definition of 'biosimilar' in European legislation and the term biosimilar should not be confused with the terms 'biobetter' and 'me-too biologic'.

A biobetter is a biological product that has been altered structurally or functionally to improve its performance. A me-too biologic is a biological medicine that targets the same pathway but is developed independently of a reference biological and is not compared to it. Neither a biobetter nor a me-too biologic can be authorised using the biosimilar route.

An applicant for approval of a biosimilar product under the biosimilar route is required to demonstrate that its product is similar to a previously authorised product. The application for approval can reference data submitted for the previously authorised product after the expiry of the data exclusivity period.

However, the use of the term 'similar' reflects the scientific reality that biological products cannot be copied precisely. Biological products are much larger and more complex than chemical pharmaceutical compounds and are produced in sensitive biological systems that can be affected by small changes in process conditions. Controlling the production of biological products, in particular any post-translational modifications, is therefore challenging. So, while it is possible to control precisely the production of generic chemical pharmaceutical compounds and to authorise them using an abridged procedure on the basis of bioequivalence data, this is not possible with biological products.

Data over and above the standard tests required for small molecule generics will therefore normally be required in order to demonstrate that a biosimilar is comparable to the reference biologic product. As a general rule, the biosimilar route requires more extensive testing and, most likely, clinical trials (which are not needed for small molecule generic drugs).

Orphan medicines

Since the pharmaceutical industry has fewer incentives, under normal market conditions, in developing and marketing medicinal products intended for rare diseases that by definition will only be used to treat small numbers of patients, the EU offers a range of incentives to encourage the development of these medicinal products – known as orphan medicines.

For a medicinal product to be classed as an orphan medicine, it must be intended for the diagnosis, prevention or treatment of either:

  • a life-threatening or chronically debilitating condition affecting no more than 5 in 10,000 people in the EU at the time of submission of the application for orphan designation; or
  • a life-threatening, seriously debilitating or serious and chronic condition where, without incentives, it would be unlikely that the revenue after marketing of the medicinal product would cover the investment in its development.

There must also be either no satisfactory method of diagnosis, prevention or treatment of the condition concerned, or, if there is such a method, the new medicine must be of significant benefit to those affected by the condition.

The principal benefit for medicinal products designated as orphan medicines is that they benefit from more generous treatment as regards market exclusivity, namely:

  • a period of 10 years from the date of marketing authorisation, which may run in parallel with the basic marketing exclusivity if the drug is also authorised (via a separate marketing authorisation) for other indications;
  • any additional orphan indications for the same product will also benefit from their own separate 10-year period of market exclusivity; and
  • where an application for a marketing authorisation for an orphan product includes the results of studies conducted in accordance with an agreed PIP, the 10-year period is extended to a period of 12 years.

Parallel imports

Parallel import regime in Europe

Parallel importation of medicinal products in the EEA relies on the principle of patent exhaustion, which itself arises from the EU's and also the EEA's treaty commitments to the free movement of goods. These freedom of movement of goods rules as regards patented medicinal products were first established in 1974 in the case of Centrafarm BV v Sterling Drug Inc2 and dictate that when a patent/SPC holder puts (or consents to the putting of) a medicinal product on the market anywhere in the EEA, the patent/SPC holder cannot object to a purchaser of those products subsequently putting them on the market in a different EEA member state, regardless of whether such import into a subsequent EEA member state would infringe the patent/SPC holder's national patent/SPC rights in the member state of destination. As a result of the differences in prices set by national governments and also by the patent/SPC owners themselves in the various different EEA states there is now a significant volume of parallel import activity.

The parallel import of medicinal products is, however, subject to significant regulation. The importer still requires a licence to import and market the product in the member state of destination, and the product packaging must meet the requirements of the member state of destination.

Parallel import licences

A parallel imported medicinal product may be distributed under an authorisation obtained through a simpler procedure than that for the initial marketing authorisation for the product. To qualify for the simplified procedure, the parallel imported medicinal product must satisfy two conditions. It must:

  • have been granted a marketing authorisation in the member state of origin; and
  • be sufficiently similar to a product that has already received marketing authorisation in the member state of destination.

The similarity between two medicinal products is considered to be sufficient when the two products have been manufactured according to the same formulation, using the same active ingredient, and have the same therapeutic effects. A parallel imported medicinal product can also be distributed under the simplified procedure even if the similar product upon which its licence is based is no longer available on the market, provided that public health requirements are met.

Repackaging of parallel imports

Repackaging will be necessary if the packaging sizes in use in the member state of origin are not permitted in the member state of destination. In principle, however, this is precluded by the trademark right of the manufacturer since all changes to the packaging or the product itself will constitute an infringement of the manufacturer's trademark. But this rule conflicts with the principle of the free movement of goods within the EEA. The case of Bristol-Myers Squibb3 has therefore ruled that certain necessary and appropriate changes are permitted, if they are made in order to eliminate obstacles in the distribution process. The so-called BMS Conditions are:

  • the use of the trademark right by the owner contributes to the artificial partitioning of the internal market;
  • the repackaging does not adversely affect the original condition of the product;
  • it is stated on the new packaging by whom the product has been manufactured and by whom it has been repackaged;
  • the presentation of the repackaged product is not such as to damage the reputation of the trademark or of its proprietor; and
  • the proprietor of the trademark receives written notice of the repackaging before the new product is put on sale and in addition, if he requests it, is supplied with a specimen of the repackaged product upon demand.

The repackaging must be necessary, and not just motivated by commercial interests. For example, repackaging is not justified for a parallel imported product that may be put on sale in the member state of destination simply by changing the labelling of the outer packaging (eg, language matters).

Compulsory licences

The availability of compulsory licences in respect of patents, especially in relation to pharmaceutical patents, has been the subject of considerable attention lately. This is mainly as a result of the Indian courts showing their willingness to grant compulsory licences in respect of pharmaceutical patents. In particular, the Indian courts recently granted a compulsory licence to an Indian generic pharmaceutical company under Bayer's patent for its cancer drug Nexavar, determining that in essence Bayer's price for Nexavar was too high. This, together with Bayer's failed challenge that India's patent legislation under which the compulsory licence was granted was not compliant with the Agreement on Trade-Related Aspects of Intellectual Property Rights (the TRIPS agreement puts restrictions on the ability of World Trade Organization members (of which India is one) to restrict the exclusive rights of patentees through – among other things – compulsory licences), has led to significant media interest in the power under national patent legislation to grant compulsory patent licences.

Article 31 of the TRIPS agreement provides that where patent legislation of World Trade Organization member states allows compulsory licences to be granted the following provisions must be included:

  • Each case must be decided on its own merits.
  • The applicant for the compulsory licence must have made efforts to take a licence from the patentee on reasonable commercial terms.
  • The scope and duration of the compulsory licence must be limited to the purpose for which it was granted, such that it may be terminated or amended if the circumstances that led to the grant of the compulsory licence change or cease to exist.
  • The patentee must be paid adequate remuneration for use under the compulsory licence.
  • The decision to grant a compulsory licence and the determination of what is adequate remuneration shall be subject to judicial review.
  • Where a compulsory licence is granted in order to enable a second patent to be exploited, the invention claimed in the second patent must involve an important technical advance of considerable economic significance in relation to the invention claimed in the first patent and the patentee of the first patent must be entitled (on reasonable terms) to a cross-licence in respect of the second patent.

This article is an extract from the Life Sciences chapter of Intellectual Property Issues in Corporate Transactions, published by Globe Law and Business, December 2015.


1. Report by the IMS Institute for Healthcare Informatics, Global Outlook for Medicines Through 2018, November 2014.

2. 15/74.

3. Joined cases C-427/93, C-429/93 and C-436/93.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions